



June 23, 2023

W. L. Gore & Associates, Inc.
Sarah Pastrnak
Regulatory Affairs Associate
1505 N. Fourth Street
Flagstaff, Arizona 86004

Re: K231505

Trade/Device Name: GORE® ACUSEAL Vascular Graft
Regulation Number: 21 CFR 870.3450
Regulation Name: Vascular Graft Prosthesis
Regulatory Class: Class II
Product Code: DSY
Dated: May 23, 2023
Received: May 24, 2023

Dear Sarah Pastrnak:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's

requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance>) and CDRH Learn (<https://www.fda.gov/training-and-continuing-education/cdrh-learn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice>) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Rohini Retarekar -S

for Carmen Johnson, Ph.D.
Assistant Director
DHT2B: Division of Circulatory Support,
Structural and Vascular Devices
OHT2: Office of Cardiovascular Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known)

K231505

Device Name

GORE® ACUSEAL Vascular Graft

Indications for Use (Describe)

GORE® ACUSEAL Vascular Graft is intended for use as a vascular prosthesis in patients requiring vascular access.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRASStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

K231505 510(k) Summary

510(k) Submitter

W. L. Gore & Associates, Inc.
1505 North Fourth St
Flagstaff, AZ 86004

Regulatory Contact: Sarah Pastrnak

Phone: 928 864 4146

E-mail: spastrna@wlgore.com

Date Prepared

23 June 2023

Device Names/Classification

Device Name: GORE® ACUSEAL Vascular Graft

Classification Name: Vascular Graft

Regulation: 21 CFR 870.3450

Classification: II

Product Code: DSY

Predicate Devices

K130215, GORE® ACUSEAL Vascular Graft

Device Description

GORE® ACUSEAL Vascular Graft is intended for use as a vascular prosthesis in patients requiring vascular access. The GORE® ACUSEAL Vascular Graft is a multi-layer vascular graft with a low bleed layer between the inner and outer layers of ePTFE (expanded polytetrafluoroethylene). The luminal surface of the inner graft component is coated with the CBAS® Heparin Surface.

Indications for Use

GORE® ACUSEAL Vascular Graft is intended for use as a vascular prosthesis in patients requiring vascular access.

Differences in Technological Characteristics

The subject and predicate GORE® ACUSEAL Vascular Graft have the same clinical use, indications for use, fundamental technology, materials, sterilization, and same intended use.

The subject GORE® ACUSEAL Vascular Graft permits the use of an additional packaging configuration and additional device configurations with different diameters.

Summary of Performance Testing

As determined by the risk analysis, the following testing was performed to demonstrate substantial equivalence to the predicate device:

- Packaging Integrity
- Packaging shelf-life evaluation
- Coating performance testing
- Sterilization testing
- Dimensional evaluation
- Burst Strength
- Suture Pullout Strength
- Tensile Strength
- Water Entry Pressure
- Kink Radius
- Puncture Burst
- Puncture Leak
- Suture Line Leak

Conclusion

The GORE® ACUSEAL Vascular Graft is substantially equivalent to the predicate device. The additional packaging configuration and device configurations did not raise new types of safety or effectiveness questions, and the testing provided in this application supports a determination of substantial equivalence.